Medscape is available in 5 Language Editions – Choose your Edition here.


Immune Thrombocytopenia and Pregnancy Treatment & Management

  • Author: Muhammad A Mir, MD, FACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
Updated: Oct 09, 2015

Medical Care

In pregnancy, treatment for immune thrombocytopenic purpura (ITP) and neonatal alloimmune thrombocytopenia (NAIT) involves two patients: the mother and the fetus.

In cases of ITP, care of the mother centers on minimizing her risk of bleeding during pregnancy and childbirth. Check platelet counts regularly throughout gestation to verify that they are in an acceptable range. Conservatively, platelet counts should be checked monthly during pregnancy (platelet counts should be checked at least every trimester even in completely stable patients).

Spontaneous bleeding seldom occurs if the maternal platelet count is greater than 20,000/µL; therefore, treatment is not indicated in the absence of bleeding unless the platelet count falls below this level. Intraoperative or intrapartum bleeding complications are unusual if the platelet count is greater than 50,000/µL; therefore, administer treatment if the platelet count is less than this prior to delivery.[20] A history of ITP in a mother or ITP in a previous pregnancy is not a contraindication to future pregnancies.[21]

One trial evaluated the safety of breastfeeding in women with ITP and did not document thrombocytopenia developing in any breastfed infants.[16] IgG antiplatelet antibodies are transmitted through the breast milk, so consider monitoring the platelet counts in breastfed newborns of mothers with ITP.

The major neonatal concern in ITP is the risk of fetal or newborn intracranial or visceral hemorrhage due to severe thrombocytopenia. Newborn thrombocytopenia is difficult to predict because newborn platelet counts do not always correlate with maternal platelet counts[2] or antiplatelet antibody titers.[8] It does correlate with the platelet count of previous first and second siblings at birth.[22] Maternal platelet counts that fall within the reference range after previous splenectomy or corticosteroid treatment do not guarantee a fetal platelet count within the reference range. In fact, splenectomy prior to pregnancy has been reported as a risk factor for the development of newborn thrombocytopenia.[23] Splenectomy possibly increases the amount of free antiplatelet antibody in the maternal sera due to the removal of the platelet/antibody destruction site.[24]

Fetal platelet counts can be obtained by fetal scalp sampling during labor or cordocentesis at 38-39 weeks' estimated gestational age; however, neither is reliable at predicting thrombocytopenia at birth. Fetal scalp sampling is technically difficult and often unreliable.[25] Owing to the risk of hemorrhage in the fetus and possible inaccuracy of the fetal platelet count, it is best avoided.[26] In a clinical trial, platelet counts were obtained by cordocentesis in 42 women with ITP. Two of the 42 newborns had severe thrombocytopenia at birth; neither was detected with cordocentesis.[27] At present, no reliable method of determining which newborns are at risk for severe thrombocytopenia exists.

A platelet count at birth is recommended. Peripheral blood is preferred over heel sticks or cord samples because of better accuracy. A cranial ultrasound should be considered if the platelet count is less than 50,000/µL, even in the absence of symptoms. Intramuscular injections such as vitamin K are best avoided.[15]

Some investigators have recommended performing a cesarean delivery in all women with ITP to minimize the trauma to the newborn during the birth process. Cesarean delivery has not been demonstrated to prevent bleeding complications in thrombocytopenic newborns. In a review of 474 newborns born to mothers with ITP, 29% of newborns born vaginally experienced a bleeding complication, compared to 30% of newborns born via cesarean delivery.[28] Reviews published to date comparing vaginal birth to cesarean delivery in women with ITP are retrospective studies; none are randomized controlled trials. However, in the absence of any clear benefit to the neonate (given the low rate of intracranial hemorrhage in infants born to mothers with ITP), cesarean delivery should be reserved for the usual obstetrical indications.

In women with a history of delivering a significantly thrombocytopenic newborn (platelet < 50,000/µL) or a newborn with an intracranial hemorrhage (platelet count < 100,000/µL) in whom other illnesses commonly associated with thrombocytopenia have been excluded,[29] test for NAIT. Perform maternal platelet antigen typing and confirm the presence of maternal antiplatelet antibodies with specificity for paternal platelets. Perform antigen typing and zygosity testing on the father of the baby to determine if platelet antigen incompatibility between the parents exists and if all potential offspring will be at risk for NAIT. If the father is a heterozygote, each subsequent fetus has only a 50% chance of being affected. Fetal platelet typing can be performed on a chorionic villous sample, amniocytes, or fetal blood to determine if the fetus carries the significant paternally derived antigen.

Prospective screening programs have demonstrated that NAIT usually develops in babies born to women with detectable antiplatelet antibody.[9] Some investigators have suggested all pregnant women presenting for prenatal care be typed for platelet alloantigen to determine if they are at risk for NAIT. Women at risk can be tested for the presence of platelet alloantibodies twice during gestation (similar to current screening programs for Rh disease). A comparison of the effectiveness of this type of screening program estimated a cost of $45,000 per case of alloimmunization diagnosed in whites.[9] The cost would be higher if testing were initiated in women of other ethnic groups because the rate of NAIT is lower in nonwhite women. At present, universal prenatal screening is not recommended because a clear clinical benefit has not been demonstrated.[10, 30]


Surgical Care

Splenectomy is an appropriate treatment for women with ITP with severe thrombocytopenia that is refractory to medical therapy. Approximately two thirds of patients have a positive response, generally within a few days. Splenectomy is seldom performed during pregnancy because most patients can be managed medically. If splenectomy is indicated, it should be performed in the second trimester. Surgical interventions requiring general anesthesia are avoided in the first trimester if possible to prevent fetal medication exposures during embryogenesis. Splenectomy is technically difficult in the third trimester because the enlarging uterus limits exposure to the spleen. Successful splenectomy has been reported during cesarean delivery.[31]

Women with splenectomies should be immunized against pneumococcus, meningococcus, and Haemophilus influenzae.[10]



Consulting a surgeon may be appropriate if splenectomy is indicated in a pregnant woman with ITP. A hematologist can be consulted if the patient with ITP or NAIT is not responding to standard therapies or requires transfusions.



Women with ITP and severe thrombocytopenia should avoid activities that are likely to result in trauma.

Contributor Information and Disclosures

Muhammad A Mir, MD, FACP Assistant Professor of Medicine (Hematology, Blood/Marrow Transplant) Milton S Hershey Medical Center, Pennsylvania State University College of Medicine

Muhammad A Mir, MD, FACP is a member of the following medical societies: American College of Physicians, American Society of Hematology, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Srikanth Nagalla, MBBS, MS, FACP Director, Clinical Hematology, Cardeza Foundation for Hematologic Research; Assistant Professor of Medicine, Division of Hematology, Associate Program Director, Hematology/Medical Oncology Fellowship, Assistant Program Director, Internal Medicine Residency, Jefferson Medical College of Thomas Jefferson University

Srikanth Nagalla, MBBS, MS, FACP is a member of the following medical societies: American Society of Hematology, Association of Specialty Professors

Disclosure: Nothing to disclose.


Wadie F Bahou, MD Chief, Division of Hematology, Hematology/Oncology Fellowship Director, Professor, Department of Internal Medicine, State University of New York at Stony Brook

Wadie F Bahou, MD is a member of the following medical societies: American Society of Hematology

Disclosure: Nothing to disclose.

Lynnae Millar, MD Professor, Chair, Department of Obstetrics and Gynecology, University of Hawaii, John A Burns School of Medicine

Lynnae Millar, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Obstetricians and Gynecologists, American Medical Association, and Society for Maternal-Fetal Medicine

Disclosure: Nothing to disclose.

  1. Burrows RF, Kelton JG. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. Am J Obstet Gynecol. 1990 Mar. 162(3):731-4. [Medline].

  2. Sainio S, Jarvenpaa AL, Renlund M. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol. 2000 Mar. 95(3):441-6. [Medline].

  3. Blanchette VS, Chen L, de Friedberg ZS. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol. 1990 Feb. 74(2):209-15. [Medline].

  4. Dreyfus M, Kaplan C, Verdy E. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood. 1997 Jun 15. 89(12):4402-6. [Medline].

  5. Davis GL. Platelet specific alloantigens. Clin Lab Sci. 1998 Nov-Dec. 11(6):356-61. [Medline].

  6. Bussel JB. Immune thrombocytopenia in pregnancy: autoimmune and alloimmune. J Reprod Immunol. 1997 Dec 15. 37(1):35-61. [Medline].

  7. Yamada H, Kato EH, Kobashi G. Passive immune thrombocytopenia in neonates of mothers with idiopathic thrombocytopenic purpura: incidence and risk factors. Semin Thromb Hemost. 1999. 25(5):491-6. [Medline].

  8. Biswas A, Arulkumaran S, Ratnam SS. Disorders of platelets in pregnancy. Obstet Gynecol Surv. 1994 Aug. 49(8):585-94. [Medline].

  9. Durand-Zaleski I, Schlegel N, Blum-Boisgard C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group. Am J Perinatol. 1996 Oct. 13(7):423-31. [Medline].

  10. ACOG practice bulletin, American College of Obstetricians and Gynecologists. Thrombocytopenia in pregnancy. Number 6, September 1999. Clinical management guidelines for obstetrician- gynecologists. Int J Gynaecol Obstet. 1999 Nov. 67(2):117-28. [Medline].

  11. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994 Nov 3. 331(18):1207-11. [Medline].

  12. Herman JH, Jumbelic MI, Ancona RJ. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pediatr Hematol Oncol. 1986 Winter. 8(4):312-7. [Medline].

  13. Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. Semin Thromb Hemost. 2011 Sep. 37(6):640-52. [Medline].

  14. Koyama S, Tomimatsu T, Kanagawa T, Kumasawa K, Tsutsui T, Kimura T. Reliable predictors of neonatal immune thrombocytopenia in pregnant women with idiopathic thrombocytopenic purpura. Am J Hematol. 2012 Jan. 87(1):15-21. [Medline].

  15. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013 Jan 3. 121(1):38-47. [Medline].

  16. Christiaens GC, Nieuwenhuis HK, von dem Borne AE. Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol. 1990 Oct. 97(10):893-8. [Medline].

  17. Gresikova M. Learning from errors: when a low platelet count in neonate excludes immune thrombocytopenic purpura in mother. Bratisl Lek Listy. 2013. 114(4):232-6. [Medline].

  18. Cohen DL, Baglin TP. Assessment and management of immune thrombocytopenia in pregnancy and in neonates. Arch Dis Child Fetal Neonatal Ed. 1995 Jan. 72(1):F71-6. [Medline].

  19. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002 Mar 28. 346(13):995-1008. [Medline].

  20. Nicolescu A, Vladareanu AM, Voican I, Onisai M, Vladareanu R. Therapeutic Options for Immune Thrombocytopenia (ITP) During Pregnancy. Maedica (Buchar). 2013 Jun. 8(2):182-188. [Medline]. [Full Text].

  21. Gernsheimer TB. Thrombocytopenia in pregnancy: is this immune thrombocytopenia or...?. Hematology Am Soc Hematol Educ Program. 2012. 2012:198-202. [Medline].

  22. Kawaguchi K, Matsubara K, Takafuta T, Shinzato I, Tanaka Y, Iwata A, et al. Factors predictive of neonatal thrombocytopenia in pregnant women with immune thrombocytopenia. Int J Hematol. 2014 May. 99(5):570-6. [Medline].

  23. Yamada H, Kato EH, Kishida T. Risk factors for neonatal thrombocytopenia in pregnancy complicated by idiopathic thrombocytopenic purpura. Ann Hematol. 1998 May. 76(5):211-4. [Medline].

  24. Mahey R, Kaur SD, Chumber S, Kriplani A, Bhatla N. Splenectomy during pregnancy: treatment of refractory immune thrombocytopenic purpura. BMJ Case Rep. 2013 Dec 20. 2013:[Medline].

  25. Moise KJ Jr, Patton DE, Cano LE. Misdiagnosis of a normal fetal platelet count after coagulation of intrapartum scalp samples in autoimmune thrombocytopenic purpura. Am J Perinatol. 1991 Sep. 8(5):295-6. [Medline].

  26. Burrows RF, Kelton JG. Pregnancy in patients with idiopathic thrombocytopenic purpura: assessing the risks for the infant at delivery. Obstet Gynecol Surv. 1993 Dec. 48(12):781-8. [Medline].

  27. Berry SM, Leonardi MR, Wolfe HM. Maternal thrombocytopenia. Predicting neonatal thrombocytopenia with cordocentesis. J Reprod Med. 1997 May. 42(5):276-80. [Medline].

  28. Cook RL, Miller RC, Katz VL. Immune thrombocytopenic purpura in pregnancy: a reappraisal of management. Obstet Gynecol. 1991 Oct. 78(4):578-83. [Medline].

  29. Bussel J, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillieres Clin Haematol. 1998 Jun. 11(2):391-408. [Medline].

  30. Kawaguchi K, Matsubara K, Takafuta T, Shinzato I, Tanaka Y, Iwata A, et al. Factors predictive of neonatal thrombocytopenia in pregnant women with immune thrombocytopenia. Int J Hematol. 2014 Mar 13. [Medline].

  31. Mahey R, Kaur SD, Chumber S, Kriplani A, Bhatla N. Splenectomy during pregnancy: treatment of refractory immune thrombocytopenic purpura. BMJ Case Rep. 2013 Dec 20. 2013:[Medline].

  32. Martí-Carvajal AJ, Peña-Martí GE, Comunián-Carrasco G. Medical treatments for idiopathic thrombocytopenic purpura during pregnancy. Cochrane Database Syst Rev. 2009 Oct 7. CD007722. [Medline].

  33. Sukenik-Halevy R, Ellis MH, Fejgin MD. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008 Mar. 63(3):182-8. [Medline].

  34. Gasim T. Immune thrombocytopenic purpura in pregnancy: a reappraisal of obstetric management and outcome. J Reprod Med. 2011 Mar-Apr. 56(3-4):163-8. [Medline].

  35. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000 Dec. 62(6):385-92. [Medline].

  36. Howman RA, Barr AL, Shand AW, Dickinson JE. Antenatal intravenous immunoglobulin in chronic immune thrombocytopenic purpura: case report and literature review. Fetal Diagn Ther. 2009. 25(1):93-7. [Medline].

  37. van der Lugt NM, van Kampen A, Walther FJ, Brand A, Lopriore E. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang. 2013 Oct. 105(3):236-43. [Medline].

  38. Bussel JB, Graziano JN, Kimberly RP. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991 May 1. 77(9):1884-93. [Medline].

  39. Scaradavou A, Woo B, Woloski BM. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997 Apr 15. 89(8):2689-700. [Medline].

  40. Nicolescu A, Vladareanu AM, Voican I, Onisai M, Vladareanu R. Therapeutic Options for Immune Thrombocytopenia (ITP) During Pregnancy. Maedica (Buchar). 2013 Jun. 8(2):182-188. [Medline].

  41. Copel JA, Gollin YG, Grannum PA. Alloimmune disorders and pregnancy. Semin Perinatol. 1991 Jun. 15(3):251-6. [Medline].

  42. Bussel JB, Zabusky MR, Berkowitz RL. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997 Jul 3. 337(1):22-6. [Medline].

  43. Patil AS, Dotters-Katz SK, Metjian AD, James AH, Swamy GK. Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy. Obstet Gynecol. 2013 Aug. 122(2 Pt 2):483-5. [Medline]. [Full Text].

  44. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011 Feb 3. 117(5):1499-506. [Medline].

  45. Kaplan C, Daffos F, Forestier F. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood. 1988 Jul. 72(1):340-3. [Medline].

  46. Nicolini U, Tannirandorn Y, Gonzalez P. Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia. Am J Obstet Gynecol. 1990 Oct. 163(4 Pt 1):1144-6. [Medline].

  47. Murphy MF, Pullon HW, Metcalfe P. Management of fetal alloimmune thrombocytopenia by weekly in utero platelet transfusions. Vox Sang. 1990. 58(1):45-9. [Medline].

  48. Lynch L, Bussel JB, McFarland JG. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol. 1992 Jul. 80(1):67-71. [Medline].

  49. Bussel JB, Berkowitz RL, Lynch L. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996 May. 174(5):1414-23. [Medline].

  50. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2001. 185(3):683-8.

  51. Giers G, Wenzel F, Fischer J, et al. Retrospective comparison of maternal vs. HPA-matched donor platelets for treatment of fetal alloimmune thrombocytopenia. Vox Sang. 2009 Oct 27. [Medline].

  52. Monteith C, Ní Áinle F, Cooley S, Lambert JS, Kelleher B, Jackson V, et al. Hepatitis C virus-associated thrombocytopenia in pregnancy: impact upon multidisciplinary care provision. J Perinat Med. 2014 Jan. 42(1):135-8. [Medline].

Immune thrombocytopenia. Nonstress test 1 week before delivery showing a normal reactive fetal heart rate pattern.
Immune thrombocytopenia. Nonstress test 4 days before delivery showing a reactive fetal heart rate with an unusual pseudosinusoidal pattern that lasted 9 minutes.
Immune thrombocytopenia. Neonatal brain at autopsy showing extensive subdural hemorrhage.
Immune thrombocytopenia. Neonatal spine at autopsy showing extensive hemorrhage at base of spine.
Immune thrombocytopenia. An infant born with neonatal lupus syndrome and severe thrombocytopenia. Note extensive bruising and petechiae.
Immune thrombocytopenia. An infant born with a cephalohematoma.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.